Once a business recognizes that data is key to making timely and informed business decisions, the challenge then becomes how to access and absorb all the data that is, or will be, available in the near-term. And in the healthcare and pharmaceutical industries, when used properly, data is valuable currency, helping to create and/or accelerate profits.
Pharmaceutical organizations use data in everything they do. The figure I’ve included here shows some of the key phases in the pharma lifecycle; the common thread among them is that they all require data in order to be successful.
In a series of blogs to follow, I’ll highlight each of these phases using customer success stories—the challenges faced and how they were overcome—as they relate to the integration, aggregation and harmonization of complex data. Examples of the types of case studies you can expect to hear about include:
- Research and development: Analyzing information for drug and product development.
- Clinical: Conducting clinical trials, interacting with contract research organizations (CROs) and formatting information into structured models for evaluation and FDA submission.
- Manufacturing and supply chain: Accessing fully integrated financial data; streamlining source-to-settle (S2S), order to cash (OTC) and other processes; and maintaining an efficient, visible supply chain.
- Sales and marketing: Aggregating global point of sale information from different sources and harmonizing product data to enable decisions on future production and distribution.
- Outcomes and adherence: Extracting clinical notes from patient electronic health records (EHRs) using natural language processing to link symptoms and recommended solutions, and then analyzing for improvement.
- Sentiment: Inspecting social networking data to determine consumer sentiment, both positive and negative, and the volume and velocity of change in the global social spectrum.
Are there areas of your business that are challenging you with data? We’d love to hear about them and make sure they are included in the discussion.
Until next time,